Trial Profile
A Long-Term Extension Study of Lesinurad in Combination With Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and Allopurinol
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jul 2017
Price :
$35
*
At a glance
- Drugs Allopurinol (Primary) ; Lesinurad (Primary)
- Indications Gout
- Focus Registrational; Therapeutic Use
- Acronyms CLEAR Extension
- Sponsors Ardea Biosciences
- 17 Jun 2017 Pooled safety results from three large pivotal studies and their extensions (CRYSTAL, CLEAR-1, CLEAR-2, CRYSTAL extension and CLEAR extension), presented at the 18th Annual Congress of the European League Against Rheumatism
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.
- 13 Nov 2016 Integrated safety data for lesinurad based on patients from CLEAR 1, CLEAR 2, CRYSTAL, CLEAR extension and CRYSTAL extension trials were presented at the American College of Rheumatology 2016 Annual Meeting, according to an Ironwood Pharmaceuticals media release.